Nirsevimab is Effective Against Respiratory Syncytial Virus-Associated Hospitalization Among American Indian and Alaska Native Children in Their First and Second RSV Seasons in Alaska and the Southwest United States, 2023-2024.

Hammitt LL, Espinoza JS, Keck JW, Hartman RM, Alvarez-Colon G, Burrage A, Campbell AP, Cardona F, Chappell J, Christensen L, Dawood FS, Desnoyers C, Dobson J, Halasa N, Hurley C, Larsen R, McAuley JB, McMorrow ML, Menachof K, Prill M, Oxley L, Riley DP, Ritchie N, Sandoval M, Singleton RJ, Sutcliffe CG

Open source

DOI: 10.1097/inf.0000000000004942
Published: 2025 Dec 1
Container: The Pediatric infectious disease journal
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1097/inf.0000000000004942,
  title = {Nirsevimab is Effective Against Respiratory Syncytial Virus-Associated Hospitalization Among American Indian and Alaska Native Children in Their First and Second RSV Seasons in Alaska and the Southwest United States, 2023-2024.},
  author = {Hammitt LL and Espinoza JS and Keck JW and Hartman RM and Alvarez-Colon G and Burrage A and Campbell AP and Cardona F and Chappell J and Christensen L and Dawood FS and Desnoyers C and Dobson J and Halasa N and Hurley C and Larsen R and McAuley JB and McMorrow ML and Menachof K and Prill M and Oxley L and Riley DP and Ritchie N and Sandoval M and Singleton RJ and Sutcliffe CG},
  year = {2025},
  journal = {The Pediatric infectious disease journal},
  doi = {10.1097/inf.0000000000004942},
  url = {https://doi.org/10.1097/inf.0000000000004942}
}

RIS

TY  - JOUR
TI  - Nirsevimab is Effective Against Respiratory Syncytial Virus-Associated Hospitalization Among American Indian and Alaska Native Children in Their First and Second RSV Seasons in Alaska and the Southwest United States, 2023-2024.
AU  - Hammitt LL
AU  - Espinoza JS
AU  - Keck JW
AU  - Hartman RM
AU  - Alvarez-Colon G
AU  - Burrage A
AU  - Campbell AP
AU  - Cardona F
AU  - Chappell J
AU  - Christensen L
AU  - Dawood FS
AU  - Desnoyers C
AU  - Dobson J
AU  - Halasa N
AU  - Hurley C
AU  - Larsen R
AU  - McAuley JB
AU  - McMorrow ML
AU  - Menachof K
AU  - Prill M
AU  - Oxley L
AU  - Riley DP
AU  - Ritchie N
AU  - Sandoval M
AU  - Singleton RJ
AU  - Sutcliffe CG
PY  - 2025
JO  - The Pediatric infectious disease journal
DO  - 10.1097/inf.0000000000004942
UR  - https://doi.org/10.1097/inf.0000000000004942
ER  -

APA

LL, H., JS, E., JW, K., RM, H., G, A., A, B., AP, C., F, C., J, C., L, C., FS, D., C, D., J, D., N, H., C, H., R, L., JB, M., ML, M., K, M., M, P., L, O., DP, R., N, R., M, S., RJ, S., & CG, S. (2025). Nirsevimab is Effective Against Respiratory Syncytial Virus-Associated Hospitalization Among American Indian and Alaska Native Children in Their First and Second RSV Seasons in Alaska and the Southwest United States, 2023-2024.. The Pediatric infectious disease journal. https://doi.org/10.1097/inf.0000000000004942

Source records

pubmed · retrieved 2026-09-26T23:17:28.908Z